Sorafenib resistance and JNK signaling in carcinoma during extracellular matrix stiffening

Biomaterials

Volumn 35, Issue 22, 2014, Pages 5749-5759

  Nguyen, Thuy V ^a   Sleiman, Marianne ^a   Moriarty, Timothy ^a   Herrick, William G ^a   Peyton, Shelly R ^a,b  

^a University of Massachusetts Amherst   (United States)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

Drug resistance; Phosphorylcholine; Poly(ethylene glycol); Stiffness

Indexed keywords

CELL CULTURE; COLLAGEN; POLYETHYLENE GLYCOLS; STIFFNESS; TUMORS;

DRUG RESISTANCE; EXTRACELLULAR MATRICES; MICROENVIRONMENTS; PHOSPHORYLCHOLINE; SIGNALING PATHWAYS; SUSTAINED ACTIVATION; TRIPLE-NEGATIVE BREAST CANCERS; TUMOR PROGRESSIONS;

ENZYME INHIBITION;

BETA1 INTEGRIN; MACROGOL; PHOSPHORYLCHOLINE; SORAFENIB; STRESS ACTIVATED PROTEIN KINASE; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; COLLAGEN; NICOTINAMIDE; PROTEIN KINASE INHIBITOR;

ARTICLE; BREAST CANCER CELL LINE; CARCINOMA; CONTROLLED STUDY; DRUG SCREENING; ENZYME INHIBITION; EXTRACELLULAR MATRIX; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HYDROGEL; IN VIVO STUDY; LIVER CANCER CELL LINE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR MICROENVIRONMENT; ANALOGS AND DERIVATIVES; BIOMECHANICS; BREAST; BREAST NEOPLASMS; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; ENZYMOLOGY; FEMALE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BIOMECHANICAL PHENOMENA; BREAST; BREAST NEOPLASMS; CARCINOMA; CELL LINE, TUMOR; COLLAGEN; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR MATRIX; FEMALE; HUMANS; MAP KINASE SIGNALING SYSTEM; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS;

EID: 84899979596     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.03.058     Document Type: Article

References (73)

1. Lu P., Weaver V.M., Werb Z. The extracellular matrix: a dynamic niche in cancer progression. JCell Biol 2012, 196:395-406.
2. Pietras K., Ostman A. Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res 2010, 316:1324-1331.
3. Ostman A. The tumor microenvironment controls drug sensitivity. Nat Med 2012, 18:1332-1334.
4. Wilson T.R., Fridlyand J., Yan Y., Penuel E., Burton L., Chan E., et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012, 487:505-509.
5. Straussman R., Morikawa T., Shee K., Barzily-Rokni M., Qian Z.R., Du J., et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012, 487:500-504.
6. Bhola N.E., Balko J.M., Dugger T.C., Kuba M.G., Sanchez V., Sanders M., et al. TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer. JClin Invest 2013, 123:1348-1358.
7. Sun Y., Campisi J., Higano C., Beer T.M., Porter P., Coleman I., et al. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med 2012, 18:1359-1368.
8. Aoudjit F., Vuori K. Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene 2001, 20:4995-5004.
9. Park C.C., Zhang H., Pallavicini M., Gray J.W., Baehner F., Park C.J., et al. Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and invivo. Cancer Res 2006, 66:1526-1535.
10. Liu S., Wang J., Niu W., Liu E., Wang J., Peng C., et al. The beta6-integrin-ERK/MAP kinase pathway contributes to chemo resistance in colon cancer. Cancer Lett 2013, 328:325-334.
11. Yang X.H., Flores L.M., Li Q., Zhou P., Xu F., Krop I.E., et al. Disruption of laminin-integrin-CD151-focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists. Cancer Res 2010, 70:2256-2263.
12. Rdnnov-jessen L., Petersen O.W., Koteliansky V., Bissell M.J. The origin of the myofibroblasts in breast cancer. JClin Invest 1995, 95:859-873.
13. Paraiso K.H., Smalley K.S. Fibroblast-mediated drug resistance in cancer. Biochem Pharmacol 2013, 85:1033-1041.
14. Vong S., Kalluri R. The role of stromal myofibroblast and extracellular matrix in tumor angiogenesis. Genes Cancer 2011, 2:1139-1145.
15. Otranto M., Sarrazy V., Bonte F., Hinz B., Gabbiani G., Desmouliere A. The role of the myofibroblast in tumor stroma remodeling. Cell Adh Migr 2012, 6:203-219.
16. Yang J.D., Nakamura I., Roberts L.R. The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Semin Cancer Biol 2011, 21:35-43.
17. Levental K.R., Yu H., Kass L., Lakins J.N., Egeblad M., Erler J.T., et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009, 139:891-906.
18. Samani A., Zubovits J., Plewes D. Elastic moduli of normal and pathological human breast tissues: an inversion-technique-based investigation of 169 samples. Phys Med Biol 2007, 52:1565-1576.
19. Paszek M.J., Zahir N., Johnson K.R., Lakins J.N., Rozenberg G.I., Gefen A., et al. Tensional homeostasis and the malignant phenotype. Cancer Cell 2005, 8:241-254.
20. Condeelis J., Pollard J.W. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006, 124:263-266.
21. Egeblad M., Rasch M.G., Weaver V.M. Dynamic interplay between the collagen scaffold and tumor evolution. Curr Opin Cell Biol 2010, 22:697-706.
22. Kumar S., Weaver V.M. Mechanics, malignancy, and metastasis: the force journey of a tumor cell. Cancer Metastasis Rev 2009, 28:113-127.
23. Kim J., Asthagiri A.R. Matrix stiffening sensitizes epithelial cells to EGF and enables the loss of contact inhibition of proliferation. JCell Sci 2011, 124:1280-1287.
24. Netti P.A., Berk D.A., Swartz M.A., Grodzinsky A.J., Jain R.K. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res 2000, 60:2497-2503.
25. Kwon C.H., Wheeldon I., Kachouie N.N., Lee S.H., Bae H., Sant S., et al. Drug-eluting microarrays for cell-based screening of chemical-induced apoptosis. Anal Chem 2011, 83:4118-4125.
26. Skardal A., Smith L., Bharadwaj S., Atala A., Soker S., Zhang Y. Tissue specific synthetic ECM hydrogels for 3-D invitro maintenance of hepatocyte function. Biomaterials 2012, 33:4565-4575.
27. Timm D.M., Chen J., Sing D., Gage J.A., Haisler W.L., Neeley S.K., et al. Ahigh-throughput three-dimensional cell migration assay for toxicity screening with mobile device-based macroscopic image analysis. Sci Rep 2013, 3:3000.
28. Herrick W.G., Nguyen T.V., Sleiman M., McRae S., Emrick T.S., Peyton S.R. PEG-phosphorylcholine hydrogels as tunable and versatile platforms for mechanobiology. Biomacromolecules 2013, 14:2294-2304.
29. Schrader J., Gordon-Walker T.T., Aucott R.L., van Deemter M., Quaas A., Walsh S., et al. Matrix stiffness modulates proliferation, chemotherapeutic response, and dormancy in hepatocellular carcinoma cells. Hepatology 2011, 53:1192-1205.
30. Zustiak S., Nossal R., Sackett D.L. Multiwell stiffness assay for the study of cell responsiveness to cytotoxic drugss. Biotechnol Bioeng 2013, 9999:1-8.
31. Liu L., Cao Y., Chen C., Zhang X., McNabola A., Wilkie D., et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006, 66:11851-11858.
32. Khatiwala C.B., Kim P.D., Peyton S.R., Putnam A.J. ECM compliance regulates osteogenesis by influencing MAPK signaling downstream of RhoA and ROCK. JBone Miner Res 2009, 24:886-898.
33. Xie B., Wang D.H., Spechler S.J. Sorafenib for treatment of hepatocellular carcinoma: a systematic review. Dig Dis Sci 2012, 57:1122-1129.
34. Tian B., Li Y., Ji X.N., Chen J., Xue Q., Ye S.L., et al. Basement membrane proteins play an active role in the invasive process of human hepatocellular carcinoma cells with high metastasis potential. JCancer Res Clin Oncol 2005, 131:80-86.
35. Escudier B., Eisen T., Stadler W.M., Szczylik C., Oudard S., Staehler M., et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. JClin Oncol 2009, 27:3312-3318.
36. Gupta-Abramson V., Troxel A.B., Nellore A., Puttaswamy K., Redlinger M., Ransone K., et al. Phase II trial of sorafenib in advanced thyroid cancer. JClin Oncol 2008, 26:4714-4719.
37. Ridley A.J. Rho GTPases and cell migration. JCell Sci 2001, 114:2713-2722.
38. Ezzoukhry Z., Louandre C., Trecherel E., Godin C., Chauffert B., Dupont S., et al. EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib. Int J Cancer 2012, 131:2961-2969.
39. Mendoza M.C., Er E.E., Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci 2011, 36:320-328.
40. Klein E.A., Yin L., Kothapalli D., Castagnino P., Byfield F.J., Xu T., et al. Cell-cycle control by physiological matrix elasticity and invivo tissue stiffening. Curr Biol 2009, 19:1511-1518.
41. Mih J.D., Sharif A.S., Liu F., Marinkovic A., Symer M.M., Tschumperlin D.J. Amultiwell platform for studying stiffness-dependent cell biology. PLoS One 2011, 6:e19929.
42. Tilghman R.W., Cowan C.R., Mih J.D., Koryakina Y., Gioeli D., Slack-Davis J.K., et al. Matrix rigidity regulates cancer cell growth and cellular phenotype. PLoS One 2010, 5:e12905.
43. Ulrich T.A., de Juan Pardo E.M., Kumar S. The mechanical rigidity of the extracellular matrix regulates the structure, motility, and proliferation of glioma cells. Cancer Res 2009, 69:4167-4174.
44. Geiger B., Spatz J.P., Bershadsky A.D. Environmental sensing through focal adhesions. Nat Rev Mol Cell Biol 2009, 10:21-33.
45. Wang H.B., Dembo M., Hanks S.K., Wang Y. Focal adhesion kinase is involved in mechanosensing during fibroblast migration. Proc Natl Acad Sci U S A 2001, 98:11295-11300.
46. Humphries J.D., Byron A., Humphries M.J. Integrin ligands at a glance. JCell Sci 2006, 119:3901-3903.
47. Sethi T., Rintoul R.C., Moore S.M., MacKinnon A.C., Salter D., Choo C., et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance invivo. Nat Med 1999, 5:662-668.
48. Cabodi S., Moro L., Bergatto E., Boeri Erba E., Di Stefano P., Turco E., et al. Integrin regulation of epidermal growth factor (EGF) receptor and of EGF-dependent responses. Biochem Soc Trans 2004, 32:438-442.
49. Huveneers S., Danen E.H.J. Adhesion signaling - crosstalk between integrins, Src and Rho. JCell Sci 2009, 122:1059-1069.
50. Manning A.M., Davis R.J. Targeting JNK for therapeutic benefit: from junk to gold?. Nat Rev Drug Discov 2003, 2:554-565.
51. Tournier C. The 2 faces of JNK signaling in cancer. Genes Cancer 2013, 4:397-400.
52. Cellurale C., Sabio G., Kennedy N.J., Das M., Barlow M., Sandy P., et al. Requirement of c-Jun NH(2)-terminal kinase for Ras-initiated tumor formation. Mol Cell Biol 2011, 31:1565-1576.
53. Hess P., Pihan G., Sawyers C.L., Flavell R.A., Davis R.J. Survival signaling mediated by c-Jun NH(2)-terminal kinase in transformed B lymphoblasts. Nat Genet 2002, 32:201-205.
54. Sakurai T., Maeda S., Chang L., Karin M. Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc Natl Acad Sci U S A 2006, 103:10544-10551.
55. Wang J., Kuiatse I., Lee A.V., Pan J., Giuliano A., Cui X. Sustained c-Jun-NH2-kinase activity promotes epithelial-mesenchymal transition, invasion, and survival of breast cancer cells by regulating extracellular signal-regulated kinase activation. Mol Cancer Res 2010, 8:266-277.
56. Cellurale C., Girnius N., Jiang F., Cavanagh-Kyros J., Lu S., Garlick D.S., et al. Role of JNK in mammary gland development and breast cancer. Cancer Res 2012, 72:472-481.
57. Cellurale C., Weston C.R., Reilly J., Garlick D.S., Jerry D.J., Sluss H.K., et al. Role of JNK in a Trp53-dependent mouse model of breast cancer. PLoS One 2010, 5:e12469.
58. Das M., Garlick D.S., Greiner D.L., Davis R.J. The role of JNK in the development of hepatocellular carcinoma. Genes Dev 2011, 25:634-645.
59. Hübner A., Mulholland D.J., Standen C.L., Karasarides M., Cavanagh-kyros J. JNK and PTEN cooperatively control the development of invasive adenocarcinoma of the prostate. Proc Natl Acad Sci U S A 2012, 109:12046-12051.
60. Coso O.A., Chiariello M., Yu J.C., Teramoto H., Crespo P., Xu N., et al. The small GTP-binding proteins Rac1 and Cdc42 regulate the activity of the JNK/SAPK signaling pathway. Cell 1995, 81:1137-1146.
61. Hall A. Rho GTPases and the actin cytoskeleton. Science 1998, 279:509-514.
62. Yu H., Mouw J.K., Weaver V.M. Forcing form and function: biomechanical regulation of tumor evolution. Trends Cell Biol 2011, 21:47-56.
63. Hui L., Bakiri L., Mairhorfer A., Schweifer N., Haslinger C., Kenner L., et al. p38alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat Genet 2007, 39:741-749.
64. Wada T., Stepniak E., Hui L., Leibbrandt A., Katada T., Nishina H., et al. Antagonistic control of cell fates by JNK and p38-MAPK signaling. Cell Death Differ 2008, 15:89-93.
65. Junttila M.R., Li S.P., Westermarck J. Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. FASEB J 2008, 22:954-965.
66. Shen Y.H., Godlewski J., Zhu J., Sathyanarayana P., Leaner V., Birrer M.J., et al. Cross-talk between JNK/SAPK and ERK/MAPK pathways: sustained activation of JNK blocks ERK activation by mitogenic factors. JBiol Chem 2003, 278:26715-26721.
67. Meng F., Lowell C.A. Abeta 1 integrin signaling pathway involving Src-family kinases, Cbl and PI-3 kinase is required for macrophage spreading and migration. EMBO J 1998, 17:4391-4403.
68. Hirsch E., Barberis L., Brancaccio M., Azzolino O., Xu D., Kyriakis J.M., et al. Defective Rac-mediated proliferation and survival after targeted mutation of the beta1 integrin cytodomain. JCell Biol 2002, 157:481-492.
69. Almeida E.A., Ilić D., Han Q., Hauck C.R., Jin F., Kawakatsu H., et al. Matrix survival signaling from fibronectin via focal adhesion kinase to c-Jun NH(2)-terminal kinase. JCell Biol 2000, 149:741-754.
70. Hsia D.A., Mitra S.K., Hauck C.R., Streblow D.N., Nelson J.A., Ilic D., et al. Differential regulation of cell motility and invasion by FAK. JCell Biol 2003, 160:753-767.
71. Flaim C.J., Chien S., Bhatia S.N. An extracellular matrix microarray for probing cellular differentiation. Nat Methods 2005, 2:119-125.
72. Anderson D.G., Putnam D., Lavik E.B., Mahmood T.A., Langer R. Biomaterial microarrays: rapid, microscale screening of polymer-cell interaction. Biomaterials 2005, 26:4892-4897.
73. Khademhosseini A., Langer R., Borenstein J., Vacanti J.P. Microscale technologies for tissue engineering and biology. Proc Natl Acad Sci U S A 2006, 103:2480-2487.